US FDA Doesn't Support Creating Ultra-Orphan Designation

Agency is already approving drugs for diseases with much smaller patient populations than the traditional rare disease, officials note.

FDA entrance sign 2016

The US FDA does not seem too interested in further subdividing the size of orphan diseases to create more incentives.

The so-called ultra-rare space, much smaller than a traditional rare disease, which FDA defines as affecting fewer than 200,000 people,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership